FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3186384803> ?p ?o ?g. }

• W3186384803 abstract "We aimed to evaluate the patient-reported outcomes (PROs) in a prospective phase III clinical trial, comparing neoadjuvant endocrine therapy (NET) with conventional neoadjuvant chemotherapy (NCT) in patients with hormone status positive, lymph node-positive premenopausal breast cancer (NCT01622361). The patients were randomized prospectively to either 24 weeks of NCT with adriamycin plus cyclophosphamide followed by taxane or NET with gonadotropin-releasing hormone agonist and tamoxifen. The patients were examined at the surgery unit of a large tertiary care hospital with a comprehensive cancer center. PROs were assessed on the first day of the trial (day 1, baseline) and at the end of treatment, using the breast cancer module of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 23 (EORTC QLQ BR23). One hundred and eighty-seven patients were randomly assigned to chemotherapy (n=95) or endocrine therapy (n=92), and 174 patients completed 24 weeks of the neoadjuvant treatment period (n=87, in each group). Baseline scores were similar between the groups. After treatment, there were no statistically significant differences in the function scales, including body image, sexual functioning, and sexual enjoyment between the groups, although the endocrine treatment group showed a significant improvement in the future perspective (hazard ratio, 8.3; 95% confidence interval, 1.72-18.38; P = 0.021). Similarly, there were no statistically significant differences in the symptom scales between the groups, including adverse effects of systemic therapy, breast symptoms, arm symptoms, and upset about hair loss. In conclusion, overall PROs were similar in both treatment groups, except for future perspective, which was significantly better in the NET group than in the NCT group.ClinicalTrials.Gov, identifier NCT01622361." @default.
• W3186384803 created "2021-08-02" @default.
• W3186384803 creator A5001408430 @default.
• W3186384803 creator A5004494566 @default.
• W3186384803 creator A5010518834 @default.
• W3186384803 creator A5010781894 @default.
• W3186384803 creator A5010796867 @default.
• W3186384803 creator A5013544822 @default.
• W3186384803 creator A5037295746 @default.
• W3186384803 creator A5052099934 @default.
• W3186384803 creator A5057636290 @default.
• W3186384803 creator A5082400192 @default.
• W3186384803 creator A5085180691 @default.
• W3186384803 date "2021-07-02" @default.
• W3186384803 modified "2023-10-18" @default.
• W3186384803 title "Patient-Reported Outcomes From Phase III Neoadjuvant Systemic Trial Comparing Neoadjuvant Chemotherapy With Neoadjuvant Endocrine Therapy in Pre-Menopausal Patients With Estrogen Receptor-Positive and HER2-Negative, Lymph Node-Positive Breast Cancer" @default.
• W3186384803 cites W1831219571 @default.
• W3186384803 cites W1892289545 @default.
• W3186384803 cites W1900328804 @default.
• W3186384803 cites W1955397179 @default.
• W3186384803 cites W1966511998 @default.
• W3186384803 cites W1966987047 @default.
• W3186384803 cites W1977047721 @default.
• W3186384803 cites W1996753689 @default.
• W3186384803 cites W2010636619 @default.
• W3186384803 cites W2016647365 @default.
• W3186384803 cites W2017182699 @default.
• W3186384803 cites W2021005684 @default.
• W3186384803 cites W2033789147 @default.
• W3186384803 cites W2034100757 @default.
• W3186384803 cites W2038104021 @default.
• W3186384803 cites W2039784427 @default.
• W3186384803 cites W2052323088 @default.
• W3186384803 cites W2053918783 @default.
• W3186384803 cites W2055560401 @default.
• W3186384803 cites W2055759954 @default.
• W3186384803 cites W2056446966 @default.
• W3186384803 cites W2058017479 @default.
• W3186384803 cites W2086801430 @default.
• W3186384803 cites W2091718376 @default.
• W3186384803 cites W2101403785 @default.
• W3186384803 cites W2102908828 @default.
• W3186384803 cites W2103758231 @default.
• W3186384803 cites W2109496096 @default.
• W3186384803 cites W2131915049 @default.
• W3186384803 cites W2134839096 @default.
• W3186384803 cites W2135404867 @default.
• W3186384803 cites W2137971505 @default.
• W3186384803 cites W2141051403 @default.
• W3186384803 cites W2149568734 @default.
• W3186384803 cites W2151799362 @default.
• W3186384803 cites W2153504606 @default.
• W3186384803 cites W2157652647 @default.
• W3186384803 cites W2162739295 @default.
• W3186384803 cites W2163995194 @default.
• W3186384803 cites W2314200711 @default.
• W3186384803 cites W2339214119 @default.
• W3186384803 cites W2732225635 @default.
• W3186384803 cites W2740663456 @default.
• W3186384803 cites W2797884904 @default.
• W3186384803 cites W2980243529 @default.
• W3186384803 cites W3030529007 @default.
• W3186384803 cites W3119607706 @default.
• W3186384803 doi "https://doi.org/10.3389/fonc.2021.608207" @default.
• W3186384803 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8284076" @default.
• W3186384803 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34277393" @default.
• W3186384803 hasPublicationYear "2021" @default.
• W3186384803 type Work @default.
• W3186384803 sameAs 3186384803 @default.
• W3186384803 citedByCount "0" @default.
• W3186384803 crossrefType "journal-article" @default.
• W3186384803 hasAuthorship W3186384803A5001408430 @default.
• W3186384803 hasAuthorship W3186384803A5004494566 @default.
• W3186384803 hasAuthorship W3186384803A5010518834 @default.
• W3186384803 hasAuthorship W3186384803A5010781894 @default.
• W3186384803 hasAuthorship W3186384803A5010796867 @default.
• W3186384803 hasAuthorship W3186384803A5013544822 @default.
• W3186384803 hasAuthorship W3186384803A5037295746 @default.
• W3186384803 hasAuthorship W3186384803A5052099934 @default.
• W3186384803 hasAuthorship W3186384803A5057636290 @default.
• W3186384803 hasAuthorship W3186384803A5082400192 @default.
• W3186384803 hasAuthorship W3186384803A5085180691 @default.
• W3186384803 hasBestOaLocation W31863848031 @default.
• W3186384803 hasConcept C121608353 @default.
• W3186384803 hasConcept C126322002 @default.
• W3186384803 hasConcept C143998085 @default.
• W3186384803 hasConcept C207103383 @default.
• W3186384803 hasConcept C2776694085 @default.
• W3186384803 hasConcept C2777176818 @default.
• W3186384803 hasConcept C2777511904 @default.
• W3186384803 hasConcept C2778292576 @default.
• W3186384803 hasConcept C29456083 @default.
• W3186384803 hasConcept C44249647 @default.
• W3186384803 hasConcept C530470458 @default.
• W3186384803 hasConcept C71924100 @default.
• W3186384803 hasConceptScore W3186384803C121608353 @default.
• W3186384803 hasConceptScore W3186384803C126322002 @default.
• W3186384803 hasConceptScore W3186384803C143998085 @default.
• W3186384803 hasConceptScore W3186384803C207103383 @default.
• W3186384803 hasConceptScore W3186384803C2776694085 @default.

• next